EASD 2018 Highlights
Below is a compilation of our top-level learnings from the EASD meeting in Berlin. Click on a headline to read more!
1. FreeStyle Libre 2: New features and accuracy results
2. HARMONY results reveal Tanzeum significantly reduces risk of heart attacks
3. Time-in-range, hypoglycemia predict complications independent of A1C
4. The most exciting therapy candidates currently in development
5. Dexcom G6 launches in Germany; real-world data on G5 vs. G6 impact on lows
6. Leaders call for heart-outcomes research in people with type 1
9. Reducing glycemic variability decreases time in hypoglycemia, regardless of average glucose
10. Lilly’s Dual GIP and GLP-1 Agonist Shows Impressive A1C Lowering and Weight Loss
11. What is “normal” CGM Data in Adults and Kids Without Diabetes?
12. Cambridge 12-week Hybrid Closed Loop Study: +3 Hour/Day Time-in-Range, -0.4% A1C Advantage
13. EASE Phase 3 Results Show Lower Dose of SGLT-2 Inhibitor Jardiance in Type 1 Reduces DKA Risk
14. New Diabetes Care Guidelines from ADA and EASD for Adults with Type 2 Diabetes
15. Professor Thomas Danne on Time-in-Range and Outcomes Beyond A1C